articleThe LancetJun 3, 2019BRONZE OA

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

PMPhilippe MoreauMAMichel AttalCHCyrille HulinBABertrand ArnulfKBKarim Belhadj

Institut universitaire du cancer de Toulouse Oncopole · Hôpital Cardiologique du Haut-Lévêque · +49 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

946
total citations
FWCI
87.89
Percentile
100%
References
32
Citations per year

Authors

58

Topics & keywords

Topics
Keywords
  • Daratumumab
  • Medicine
  • Bortezomib
  • Multiple myeloma
  • Autologous stem-cell transplantation
  • Thalidomide
  • Dexamethasone
  • Transplantation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding